Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
CRYSTAL FORM OF 3-(4-METHYL-1H-IMIDAZOL-1-YL)-5-TRIFLUOROMETHYLANILINE MONOHYDROCHLORIDE AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2019/196802
Kind Code:
A1
Abstract:
The present invention relates to a crystal form of 3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylaniline monohydrochloride and the use thereof. Specifically, disclosed are a crystal form A of a monohydrochloride anhydrous substance of 3-(4-methyl-1H-imidazol-1-yl)-5-trifluoromethylaniline, a method for preparing the crystal form A and the use of the crystal form in the synthesis of nilotinib. The crystal form A of the present invention has good stability and purity, and can be directly used in the preparation and production of nilotinib. The method for preparing nilotinib in the present invention is easy to operate and has a high industrial application value.

Inventors:
NIU DELIANG (CN)
MA BOJUN (CN)
ZHU ZHANQUN (CN)
WAN QIANG (CN)
Application Number:
PCT/CN2019/081771
Publication Date:
October 17, 2019
Filing Date:
April 08, 2019
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
ARIZEST SHANGHAI PHARMATECH CO LTD (CN)
JIANGSU ACEBRIGHT PHARMACEUTICALS CO LTD (CN)
SHANGHAI ACEBRIGHT PHARMACEUTICALS GROUP CO LTD (CN)
International Classes:
C07D233/61; C07D401/14
Domestic Patent References:
WO2010009402A22010-01-21
WO2006135640A22006-12-21
WO2006135619A12006-12-21
Foreign References:
CN101189212A2008-05-28
CN102321073A2012-01-18
CN108530364A2018-09-14
US7169791B22007-01-30
Other References:
See also references of EP 3782988A4
Attorney, Agent or Firm:
XU & PARTNERS, LLC. (CN)
Download PDF: